Incannex – Positive Pre-IND Meeting with US FDA for IHL-42X for Obstructive Sleep Apnoea

Melbourne, Australia, May 17, 2022 – Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it completed a highly constructive Pre-Investigational New Drug Application (‘pre-IND’) meeting with the US Food and Drug Administration (‘FDA’) to discuss the development IHL-42X.